Dry Age-Related Macular Degeneration (AMD) Market Research Report—Global Forecast till 2027

Dry Age-Related Macular Degeneration Market: Information by Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, and Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, and Above 40 Years), By Diagnosis and Treatment[Treatment (Nutrition Therapy (Vitamins, Zinc, Copper), Telescopic Lens Implant), and Diagnosis (Fluorescein Angiogram, Preliminary Test, Optical Coherence Tomography], By Route of Administration (Oral, Injectables), by End User (Hospitals & Clinics, Diagnostic Centers, Academic Research Institutes), and by Region(North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027

ID: MRFR/HC/9174-CR | August 2021 | Region: Global | 171 pages

Dry Age-Related Macular Degeneration AMD Market Forecast


The dry AMD market is expected to cross USD 6,113.33million by 2027 at a CAGR of 8.62% during the forecast period.


Market Overview:


The growth of the global dry Age-related Macular Degeneration (AMD) market is attributed to the growing geriatric population and increasing prevalence of age-related macular degeneration, and the introduction of novel treatment methods for dry AMD coupled with the increasing number of clinical trials focused on dry AMD. Other factors like increasing healthcare expenditure are likely to help the market grow. However, the high number of failed clinical trials for dry AMD drugs might hamper the market growth to some extent.


COVID-19 Analysis:


The COVID-19 pandemic has significantly affected the dry AMD market as patients are unable to visit ophthalmologists, which has ultimately affected the total number of patient visits. Furthermore, ophthalmologists themselves are at risk here due to the close physical nature of the work. Delay in diagnosis may also lead to adverse effects in the patients, such as progression of dry AMD to advanced wet AMD. However, experts recommend patients with dry AMD maintain home monitoring and continue making healthy lifestyle choices. Telehealth is being extensively utilized for consulting with doctors virtually. The supply chain related to dietary supplements of vitamins and zinc prescribed for dry AMD is also hit. With the increasing demand for supplements for boosting immunity to fight coronavirus, the demand is not being met, which may adversely affect patients with dry AMD. However, industries are upscaling their production, and along with the easing COVID-19 conditions in several countries, the return of normalcy supply and demand is expected soon.


Several restrictions due to COVID-19 were put in place by the respective governments to control the spread of COVID-19. Restrictions such as travel restrictions and stay-at-home orders created certain limitations that impact the ability of the laboratory staff to perform their duties and potentially disrupt the supply chain adequately. Other possible impacts such as delay in project delivery timelines and storage of samples for a prolonged time due to delay may also affect results. Owing to fear amongst lab technicians and unavailability of professionals may hamper the research progress. However, due to less human-to-human involvement in non-clinical research, the impact is expected to be quite less.


Market Dynamics:


Market Drivers



  • Growing Geriatric Population and Increasing Prevalence of Dry Age-Related Macular Degeneration



According to a report published by United Nations (UN) in December 2020, the older population in the world is growing rapidly due to increasing life expectancy levels and decreasing levels of fertility. According to the same report, 727 million persons aged 65 years or over were living in 2020, and it is projected that this number would increase to 1.5 billion approximately in 2050. The proportion of the global population aged 65 and over is anticipated to rise from 9.3% in 2020 to about 16.0% in 2050. The same can be observed in China as well. The UN suggests that the share of adults aged over 65 will increase from 12% in 2020 to 26% by 2050.



  • Increasing Healthcare Expenditure


Comprehensive and comparable estimates of health spending in each country are a key input for health policy and planning and are necessary to support national and international health goals. The World Health Organization (WHO), on February 20, 2019, released a new report on global health expenditure, according to which global spending on health increased in low- and middle-income countries by 6% and in high-income countries by 4%. According to the same report, external and domestic funding roles are evolving; however, external funding is declining in middle-income countries. The governments account for less than 40% of primary health care spending.


Market Restraints



  • Failed Clinical Trials for Dry AMD


In recent years, various drugs for AMD treatment have failed to reach FDA guidelines in terms of accuracy. For instance, in 2018, lampalizumab by F. Hoffmann-La Roche AG (Switzerland) failed in its first Phase III clinical trial. Lampalizumab was expected to become the first-ever treatment for patients with dry AMD. Few other treatments that failed to pass the clinical trials stage were eculizumab which failed in its phase 2 clinical trials,emixustat hydrochloride failed in phase IIb/III, palucorcel by Janssen Pharmaceuticals, failed to pass the phase IIA clinical trials, and several more. Such failed clinical trials and stringent regulations regarding dry AMD drugs may hamper the market growth in the forecast period to an extent.


Market Opportunities



  • Increase in Pipeline Drugs for Dry AMD


Several treatment options, such as VEGF inhibitors, Photodynamic Therapy (PDT) and thermal laser photocoagulation, are available for wet AMD. Dry AMD, on the other hand, has no proven effective treatment yet. There are chances that the person suffering from dry AMD might develop wet AMD. Hence, to slow down, the progression patients are advised to stop smoking and take a specific high-dose formula of antioxidant vitamins and zinc. The "AREDS2" formula is considered the best vitamin combination as of now.


Global Dry AMDMarketShare (%), by Stages, 2020
Global Dry AMD Market Share (%), by Stages, 2020
Source: MRFR Analysis


Value Chain Analysis


The value chain analysis for the dry AMD industry comprises five major components that start with the research & product development, followed by manufacturing the products, distribution, sales, and post-sales services.


Despite the fact that clinical trials give valuable information on a drug's efficacy and safety, it is difficult to have comprehensive knowledge on a drug's safety at the time of approval. Despite the rigorous processes in the medication development process, there are limits. As a result, during the months and even years that a product spends in the marketplace, the full image of its safety emerges. Regulatory bodies review reports of problems with prescription and over-the-counter drugs and decide to add cautions to the dosage or usage information, as well as other measures for more serious issues. Post-sales monitoring forms the basis of new product development acknowledging the limitations of products.


Segment Overview


The global dry AMD market has been divided based on stages, age group, route of administration,diagnosis & treatment, and end user.


By Stages



  • Early-stage of AMD


Early-stage age-related macular degeneration holds the second largest market share due to the rising AMD patient pool in this stage. In early-stage AMD, there is no vision loss, and it is diagnoses by the presence of medium-sized drusen beneath the retina. The drusen (yellow pigments) are accumulations of amorphous debris subjacent to the basement membrane of the retinal pigment epithelium.



  • Intermediate Stage of AMD


The intermediate stage of AMD is characterized by the presence of numerous medium-sized drusen or at least one large drusen or noncentral geographic atrophy.



  • Late Stage of AMD


The intermediate stage of AMD is characterized by the presence of numerous medium-sized drusen or at least one large drusen or noncentral geographic atrophy.


By Age Group


On the basis of age group, the market is bifurcated into above 75 years, above 60 years, and above 40 years.The above 75 yearssegment accounts for the largest share and is anticipated to register a CAGR of 7.49% from 2021 to 2027.



  • Above 40 Years


Adults above 40 years may start developing vision problems, and normal changes in the eye’s focusing ability, called presbyopia, continue to progress with age. This age group is particularly at risk of dry AMD due to chronic, systemic conditions such as diabetes, family history of glaucoma, and health conditions related to high cholesterol, thyroid, or depression.



  • Above 60 Years


Adults above 60 years can start developing warning signs of age-related problems that may lead to vision loss. There is a rising incidence of AMD in the age group above 60 years is due to other eye disorders like cataracts, dry eye, diabetic retinopathy, and glaucoma.



  • Above 75 Years


This segment dominates the global dry age-related macular degeneration market by age group due to the growing prevalence of AMD in adults above 75 years and other dry age-related factors. Ithada market share of 45.23% in 2020.


By Diagnosis & Treatment


On the basis of diagnosis & treatment, the market is segmented into treatment and diagnosis. The treatment is further bifurcated into nutrition therapy and telescopic lens implant. The nutrition therapy segment is further divided into antioxidants and others.The antioxidants are further segmented into vitamins, zinc, copper, omega-3 fatty acids, and others.The diagnosis segment is further categorized into optical coherence tomography, fluorescein angiogram, preliminary test, and others.



  • Treatment


The nutrition therapy segment holds the largest market share of 90.92% in the year 2020, owing to emerging trends, numerous drugs under the pipeline, and the use of novel techniques for the treatment. Moreover, the increasing prevalence of eye-related disorders is likely to boost the global dry age-related macular degeneration market during the forecast period.



  • Diagnosis


Optical Coherence Tomography (OCT) provides a cross-sectional image of the eye used to check the thickness of the macula and fluid leaking in the retina. The retina is scanned by a machine, which produces extremely detailed pictures of the retina and macula. Optical coherence tomography is a type of imaging that uses light to create imageholds the largest market share based on the type of diagnosis.


By Route of Administration


On the basis of route of administration, the market is bifurcated into oral andinjectables. The oral route holds the largest market share of 64.32% in 2020 and is mainly used to treat age-related macular degeneration.



  • Oral


Nutrition therapy is the main preventive measure thatcan delay the process of vision loss. Zinc, copper, beta-carotenoids,and other antioxidants are prescribed for dry age-related macular degeneration. This route of administration holds the largest share of the market as most of the available clinical studies employed it.



  • Injectables


The injectables that include intravitreal, subretinal is the most preferred route for treatment associated with dry age-related macular degeneration. The treatment options in dry AMD administered by this route include the currently ongoing clinical trials related to pegcetacoplan and Zimura. Small clinical trials have shown that stem cells do not have any unexpected adverse effects.


By End User


On the basis of end-user, the market is segmented into hospitals &clinics, diagnostic centers, academic &research institutes, and others. The hospitals & clinics segmentaccounted for the largest market share of 50.24% in 2020 in the global dry age-related macular degeneration market owing to the increasing patient population getting monitored with dry AMD and increasing preference given to treatments in hospitals.



  • Hospitals & Clinics


Hospitals and clinics are dominating the global dry age-related macular degeneration market based on end user. This share is majorly attributed to the increasing number of patients getting monitored with eye diseases. Since advanced and complete treatments are available in the hospital, patients normally prefer to get treated there. Clinics are also the medical care centers thatprovide care for AMD patients.



  • Diagnostic Centers


A diagnostic center is a place that offers diagnostic services to the medical profession or the general public. It is also known as an imaging center. The services include visual acuity tests, dilated eye exams, physical examination by Amsler grid, diagnosis through imaging techniques such as fluorescein angiogram, optical coherence tomography, and others.



  • Academic & Research Institutes


Academic & research institutes isa rapidly growing segment in global age-related macular degeneration due to increasing research programs for finding the prevalence of dry AMD and new treatment options to prevent the disease. Moreover, the increasing number of researchers in the institutes is increasing the share of this segment. For instance, The National Eye Institute (NEI) launched a data portal for macular degeneration research in March 2021. This data enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease Study 2 (AREDS2).



  • Others


The others segment includes eye clinics, and ophthalmic centers held 4.04% market share in 2020. This segment is anticipated to register a CAGR of 5.82% during the forecast period.


Global Dry AMD Market Share (%), by Region, 2020
Global Dry AMD Market Share (%), by Region, 2020
Source: MRFR Analysis


Regional Analysis


The global dry AMD market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.


North America:


The Association for Research in Vision and Ophthalmology 2020 has conducted study between 2014 &2019 and concluded that dry AMD had the largest disease burden over the 6 years with a 16.3% prevalence compared to wet AMD, diabetic macular edema, diabetic retinopathy, and other indications. Furthermore, dry AMD prevalence increased with age, peaking in the 80- to 89-year-old age group. Additionally, the growing government initiatives and funding are propelling the growth of the dry age-related macular degeneration market in the North American region.


Europe:


Europe holds the second largest market share due to the increasing older population and rising patient population. Additionally, improving government initiatives, increasing healthcare frames, and rising demand for technologically innovative treatment aredriving the growth of the dry age-related macular degeneration market in Europe. For instance, Eurostat estimated that the population of older people (aged 65 years or more) in the EU-27 wouldincrease significantly, rising from 90.5 million at the start of 2019 to reach 129.8 million by 2050.


Asia-Pacific:


The Asia-Pacific is the fastest-growing market for age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, the rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. According to the WHO, 90% of total visually impaired people lived in developing countries in the Asia-Pacific region. Additionally, India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and the increasing demand for improved healthcare services.


Rest of the World:


The Rest of the World is expected to witness a restricted growth due to limited access and healthcare affordability among the population. This region is segmented into Middle East, Africa, and Latin America. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure. A study estimating the prevalence of vision loss in Sub-Saharan Africa (SSA) in 2020 estimated 4.28 million blind individuals, 17.36 million individuals with moderate-to-severe vision impairment, and 101.08 million individuals were estimated to have near vision loss.


Competitive Landscape


The global dry AMD market is expected to grow significantly in the coming years due to the growing geriatric population,rising prevalence of age-related macular degeneration, and increased healthcare expenditure globally. The global dry AMD market is characterized by the presence of several global and regional vendors. The market is highly competitive, with all the players trying to gain maximum market share. Frequent changes in government policies, intense competition, and FDA regulations are the key factors that impact global market growth. The vendors compete based on cost, product quality, reliability, and aftermarket services and try to be the first to bring a treatment for the public. It is crucial for the players to offer cost-efficient and high-quality dry AMD to succeed in an intensely competitive market environment.


The leading players, as mentioned above, are dominating the market due to their advanced product offerings, high industry experience, and regional reach. These players may establish their presence worldwide through strategic partnerships and acquisitions during the forecast period. Players having access to better technologies are capable of developing unique and innovative products, which could render the competitors’ offerings obsolete. The competitive environment in the market is likely to intensify further due to the rising number of contracts and expansions.


List of Key Companies Covered in this report:



  • Santen Pharmaceuticals Inc. (Japan)

  • Allergan plc (Ireland)

  • Bausch Health (Canada)

  • Alimera Science Inc. (US)

  • Phio Pharmaceuticals Corp (US)

  • Ocumension Therapeutics Co. Ltd (China)

  • Belite Bio Inc. (US)

  • Kubota Vision Inc. (US)

  • Iveric Bio (US)

  • Eyestem Research Pvt Ltd (India)

  • Yuyang DNU Co., Ltd (South Korea)

  • Stealth Biotherapeutics Inc. (US)


Recent Developments



  • In April2021, Alimera offered an exclusive license agreement to Ocumension Therapeutics for the commercialization of ophthalmology medicine in Asia and China. The deal signed was worth USD 20 million, in which 10 million was paid upfront, and the rest of the payment will be made based on the sales of the product.

  • In July 2020, bioMérieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry. The new BIOFIRE MYCOPLASMA test, which is available in the US, will be launched in some countries in Europe and the Asia-Pacific region in the coming months.

  • In February 2021, Stealth BioTherapeutics Corp completed its enrolment for the phase II ‘ReCLAIM-2 study’ for dry AMD drug Elamipretide.

  • In March 2020, Iveric bio announced that the FDA granted a Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in the development of the treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).


Report Overview:

The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


Global Dry Age-Related Macular DegenerationMarket, by Stages



  • Early AMD

  • Intermediate AMD

  • Late AMD


Global Dry Age-Related Macular Degeneration Market, by Age Group



  • Above 40 Years

  • Above 60 Years

  • Above 75 Years


Global Dry Age-Related Macular Degeneration Market, by Diagnosis & Treatment



  • Treatment

    • Nutrition Therapy

      • Antioxidants

        • Vitamins

        • Zinc

        • Copper

        • Omega-3 fatty acids

        • Others



      • Others



    • Telescopic Lens Implant



  • Diagnosis

    • Fluorescein Angiogram

    • Preliminary Test

    • Optical Coherence Tomography

    • Others




Global Dry Age-Related Macular Degeneration Market, by Route of Administration



  • Oral

  • Injectables


Global Dry Age-Related Macular Degeneration Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Academic Research Institutes

  • Others


Global Dry Age-Related Macular Degeneration Market, by Region



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America





Report Scope:
Report Attribute/Metric Details
  Market Size   USD 6,113.33 Million
  CAGR   8.62%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Stages, Age Group, Diagnosis & Treatment, Route of Administration, End User, and Region
  Segments Covered   Stages, Age Group, Diagnosis & Treatment, Route of Administration, End User, and Region
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   • Allergan plc (Ireland) • Bausch Health (Canada) • Eyestem Research Pvt Ltd (India)
  Key Market Opportunities   • Collaboration of major players with small players
  Key Market Drivers   • Growing geriatric population and increasing prevalence of Dry age-related macular degeneration • Increasing healthcare expenditure


TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 MARKET STRUCTURE

2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DRY AGE-RELATED MACULAR DEGENERATION

4.2.2 INCREASING HEALTHCARE EXPENDITURE

4.3 RESTRAINTS

4.3.1 FAILED CLINICAL TRAILS FOR DRY AMD

4.4 OPPORTUNITIES

4.4.1 INCREASE IN PIPELINE DRUGS FOR DRY AMD

4.4.2 DEVELOPMENT OF NEW TECHNOLOGIES FOR TREATMENT

4.5 EPIDEMIOLOGY OF DRY AMD

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE DRY AMD MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON PATIENTS WITH DRY AMD

5.3.3 IMPACT ON CLINICAL TRIALS

5.3.4 IMPACT ON R&D

5.3.5 IMPACT ON MARKET GROWTH

6 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES

6.1 OVERVIEW

6.2 EARLY AGE-RELATED MACULAR DEGENERATION

6.3 INTERMEDIATE AGE-RELATED MACULAR DEGENERATION

6.4 LATE AGE-RELATED MACULAR DEGENERATION

7 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP

7.1 OVERVIEW

7.2 ABOVE 40 YEARS

7.3 ABOVE 60 YEARS

7.4 ABOVE 75 YEARS

8 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT

8.1 OVERVIEW

8.2 TREATMENT

8.3 DIAGNOSIS

9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 ORAL

9.3 INJECTABLES

10 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL & CLINICS

10.3 DIAGNOSTIC CENTERS

10.4 ACADEMIC RESEARCH INSTITUTES

10.5 OTHERS

11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 UK

11.3.3 FRANCE

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 SOUTH KOREA

11.4.5 AUSTRALIA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST

11.5.2 AFRICA

11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 COMPETITIVEOVERVIEW

12.2 MARKET SHARE ANALYSIS

12.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DRY AMD MARKET

12.4 COMPETITIVE BENCHMARKING

12.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DRY AMD MARKET

12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.6.1 CONTRACTS & AGREEMENTS

12.6.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES

12.6.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

12.6.4 INVESTMENT

12.7 MAJOR PLAYERS FINANCIAL MATRIX

12.7.1 SALES, 2020

12.7.2 R&D EXPENDITURE, 2020

13 COMPANY PROFILES

13.1 SANTEN PHARMACEUTICALS INC.

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 PRODUCTS/SERVICES OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 ALLERGAN PLC

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 PRODUCTS/SERVICES OFFERED

13.2.4 ALLERGAN: KEY DEVELOPMENTS

13.2.5 SWOT ANALYSIS

13.2.6 KEY STRATEGIES

13.3 BAUSCH HEALTH (VALEANT PHARMACEUTICALS)

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 PRODUCTS/SERVICES OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 SWOT ANALYSIS

13.3.6 KEY STRATEGIES

13.4 ALIMERA SCIENCES INC.

13.4.1 COMPANY OVERVIEWS

13.4.2 FINANCIAL OVERVIEW

13.4.3 PRODUCTS/SERVICES OFFERED

13.4.4 KEY DEVELOPMENTS

13.4.5 SWOT ANALYSIS

13.4.6 KEY STRATEGIES

13.5 RXI PHARMACEUTICALS, INC. (PHIO PHARMACEUTICALS CORP)

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 PRODUCTS/SERVICES OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 SWOT ANALYSIS

13.5.6 KEY STRATEGIES

13.6 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD

13.6.1 COMPANY OVERVIEWS

13.6.2 FINANCIAL OVERVIEW

13.6.3 PRODUCTS/SERVICES OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 BELITE BIO INC.

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 PRODUCTS/SERVICES OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 KUBOTA VISION INC.

13.8.1 COMPANY OVERVIEW

13.8.2 FINANCIAL OVERVIEW

13.8.3 PRODUCTS/SERVICES OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 SWOT ANALYSIS

13.8.6 KEY STRATEGIES

13.9 IVERIC BIO

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 PRODUCTS/SERVICES OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 EYESTEM RESEARCH PVT LTD

13.10.1 COMPANY OVERVIEW

13.10.2 FINANCIAL OVERVIEW

13.10.3 PRODUCTS/SERVICES OFFERED

13.10.4 KEY DEVELOPMENTS

13.10.5 SWOT ANALYSIS

13.10.6 KEY STRATEGIES

13.11 YUYANG DNU CO., LTD

13.11.1 COMPANY OVERVIEW

13.11.2 FINANCIAL OVERVIEW

13.11.3 PRODUCTS/SERVICES OFFERED

13.11.4 KEY DEVELOPMENTS

13.11.5 SWOT ANALYSIS

13.11.6 KEY STRATEGIES

13.12 STEALTH BIOTHERAPEUTICS CORP

13.12.1 COMPANY OVERVIEW

13.12.2 FINANCIAL OVERVIEW

13.12.3 PRODUCTS/SERVICES OFFERED

13.12.4 KEY DEVELOPMENTS

13.12.5 SWOT ANALYSIS

13.12.6 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS

 

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 DRY AMD DRUGS ONGOING CLINICAL TRIALS

TABLE 4 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 5 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR EARLY AMD, BY REGION, 2018–2027 (USD MILLION)

TABLE 6 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR INTERMEDIATE AMD, BY REGION, 2018–2027 (USD MILLION)

TABLE 7 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR LATE AMD, BY REGION, 2018–2027 (USD MILLION)

TABLE 8 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 9 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 40 YEARS, BY REGION, 2018–2027 (USD MILLION)

TABLE 10 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ABOVE 60 YEARS, BY REGION, 2018–2027 (USD MILLION)

TABLE 11 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ABOVE 75 YEARS, BY REGION, 2018–2027 (USD MILLION)

TABLE 12 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION AMD MARKET, BY DIAGNOSIS AND TREATMENT, 2018–2027 (USD MILLION)

TABLE 13 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY REGION, 2018–2027 (USD MILLION)

TABLE 14 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 15 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 16 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITIONAL THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 17 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY REGION, 2018–2027 (USD MILLION)

TABLE 18 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 19 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 20 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ORAL, BY REGION, 2018–2027 (USD MILLION)

TABLE 21 ONGOING CLINICAL TRIALS RELATED TO AGE-RELATED MACULAR DEGENERATION, BY ROUTE OF ADMINISTRATION, 2020

TABLE 22 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR INJECTABLES, BY REGION, 2018–2027 (USD MILLION)

TABLE 23 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 24 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL & CLINICS, BY REGION, 2018–2027 (USD MILLION)

TABLE 25 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2018–2027 (USD MILLION)

TABLE 26 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018–2027 (USD MILLION)

TABLE 27 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)

TABLE 28 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2018–2027 ((USD MILLION)

TABLE 29 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 30 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 31 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 32 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 33 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 34 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 35 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 36 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 37 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 38 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 39 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 40 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 41 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 42 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 43 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 44 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 45 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 46 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 47 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 48 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 49 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 50 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 51 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 52 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 53 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 54 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 55 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 56 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 57 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 58 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 59 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 60 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 63 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 66 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 67 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 68 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 69 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 72 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 73 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 74 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 75 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 76 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 77 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 78 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 79 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 82 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 83 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 84 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 85 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 86 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 87 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 88 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 89 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 92 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 93 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 94 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 95 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 96 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 97 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 98 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 99 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 101 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 102 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 103 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 104 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 105 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 106 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 107 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 108 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 109 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 110 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 111 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 112 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 113 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 114 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 115 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 116 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 117 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 118 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 119 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 120 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 121 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 122 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 123 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 124 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 125 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 126 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 127 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 128 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 129 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 130 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 131 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 132 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 133 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 134 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 135 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 136 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 137 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 138 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 139 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 140 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 141 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 142 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 143 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 144 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 145 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 146 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 147 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 148 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 149 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 150 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 151 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 152 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 153 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 154 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 155 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 156 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 157 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 158 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 159 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 160 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 161 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 162 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 163 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 164 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 166 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 167 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 168 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 169 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 170 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 171 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 172 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 173 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 174 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 175 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 176 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)

TABLE 177 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)

TABLE 178 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)

TABLE 179 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)

TABLE 180 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 181 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)

TABLE 182 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 183 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 184 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 185 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 186 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 187 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 188 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 189 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 190 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 191 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 192 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 193 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 194 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 195 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 196 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 197 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 198 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 199 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 200 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 201 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 202 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 203 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 204 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 205 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 206 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 207 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 208 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 209 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 210 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 211 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 212 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)

TABLE 213 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)

TABLE 214 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 215 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)

TABLE 216 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)

TABLE 217 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)

TABLE 218 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)

TABLE 219 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)

TABLE 220 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 221 THE MOST ACTIVE PLAYERS IN THE GLOBAL DRY AMD MARKET

TABLE 222 CONTRACTS & AGREEMENTS

TABLE 223 NEW PRODUCT DEVELOPMENTS/LAUNCHES

TABLE 224 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

TABLE 225 INVESTMENT

TABLE 226 SANTEN PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED

TABLE 227 SANTEN PHARMACEUTICALS INC.: KEY DEVELOPMENTS

TABLE 228 ALLERGAN: PRODUCTS/SERVICES OFFERED

TABLE 229 BAUSCH HEALTH: PRODUCTS/SERVICES OFFERED

TABLE 230 BAUSCH HEALTH: KEY DEVELOPMENTS

TABLE 231 ALIMERA SCIENCES: PRODUCTS/SERVICES OFFERED

TABLE 232 RXI PHARMACEUTICALS, INC.: PRODUCTS/SERVICES OFFERED

TABLE 233 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: PRODUCTS/SERVICES OFFERED

TABLE 234 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: KEY DEVELOPMENTS

TABLE 235 BELITE BIO INC.: PRODUCTS/SERVICES OFFERED

TABLE 236 BELITE BIO INC.: KEY DEVELOPMENTS

TABLE 237 KUBOTA VISION INC.: PRODUCTS/SERVICES OFFERED

TABLE 238 IVERIC BIO: PRODUCTS/SERVICES OFFERED

TABLE 239 IVERIC BIO: KEY DEVELOPMENTS

TABLE 240 EYESTEM RESEARCH PVT LTD: PRODUCTS/SERVICES OFFERED

TABLE 241 YUYANG DNU CO., LTD: PRODUCTS/SERVICES OFFERED

TABLE 242 STEALTH BIOTHERAPEUTICS CORP: PRODUCTS/SERVICES OFFERED

TABLE 243 STEALTH BIOTHERAPEUTICS CORP: KEY DEVELOPMENTS

 

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL DRY AMD MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: DRY AGE-RELATED MACULAR DEGENERATION MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: DRY AMD MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: DRY AMD MARKET

FIGURE 9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020 & 2027 (USD MILLION)

FIGURE 10 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020 & 2027 (USD MILLION)

FIGURE 11 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020 & 2027 (USD MILLION)

FIGURE 12 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2020 & 2027 (USD MILLION)

FIGURE 13 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2020 & 2027 (USD MILLION)

FIGURE 14 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION 2020 & 2027 (USD MILLION)

FIGURE 15 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY REGION, 2020

FIGURE 16 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 17 EUROPE DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 18 ASIA-PACIFIC DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 19 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY REGION, 2020

FIGURE 20 MAJOR MANUFACTURERS MARKET SHARE ANALYSIS (%), 2020

FIGURE 21 CONTRACTS & AGREEMENTS: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DRY AMD MARKET

FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 23 SALES, 2020

FIGURE 24 MAJOR PLAYERS R&D EXPENDITURE, 2020

FIGURE 25 SANTEN PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 SANTEN PHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 27 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 ALLERGAN: SWOT ANALYSIS

FIGURE 29 BAUSCH HEALTH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 BAUSCH HEALTH: SWOT ANALYSIS

FIGURE 31 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 ALIMERA SCIENCES: KEY DEVELOPMENTS

FIGURE 33 ALIMERA SCIENCES: SWOT ANALYSIS

FIGURE 34 RXI PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 RXI PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 36 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: SWOT ANALYSIS

FIGURE 38 BELITE BIO INC.: SWOT ANALYSIS

FIGURE 39 KUBOTA VISION INC.: FINANCIAL OVERVIEW

FIGURE 40 KUBOTA VISION INC.: SWOT ANALYSIS

FIGURE 41 IVERIC BIO.: SWOT ANALYSIS

FIGURE 42 EYESTEM RESEARCH PVT Ltd: SWOT ANALYSIS

FIGURE 43 YUYANG DNU CO., LTD: SWOT ANALYSIS

FIGURE 44 STEALTH BIOTHERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 45 STEALTH BIOTHERAPEUTICS CORP: SWOT ANALYSIS



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.